Metronidazole
Metronidazole
Decades of trial support and the class's standing question: an antibiotic dispensed monthly with no stated review point is a subscription, not a course.
The marker is a representative concentration from the cited records. The bar includes approved and compounded preparations recorded here. It is not a recommended dose, a minimum effective strength or a claim that other concentrations are untested. Evidence depends on the vehicle, indication and trial population.
The shaded band is the depth this molecule is understood to reach. Anything below it is out of scope, whatever the label says.
Mechanism
Long-standing first-line agent for inflammatory rosacea lesions. The precise mechanism in rosacea is unknown; the antioxidant and anti-inflammatory activity is thought to matter more than the antibacterial.
HOUSE NOTES
- Approved at 0.75% and 1%. This register has found it compounded at 1.11%, published honestly, and unstated elsewhere.
- No product in this register that dispenses it states a duration or a review point.
- Topical metronidazole is a far smaller stewardship concern than an oral antibiotic, and a sentence about how long the course runs would still be the difference between a treatment plan and a subscription.
- One company's ingredient page concedes that the precise mechanism of its action is unknown — an unusual piece of candour on a consumer page.
MEASURED ENDPOINTS
SUPPORTING RECORDS
Layering
- Indefinite use without review
- Alcohol, for the oral form
- Azelaic acid
- Ivermectin